Tomoko Ise
YOU?
Author Swipe
View article: Generation of antagonistic biparatopic anti-CD30 antibody from an agonistic antibody by precise epitope determination and utilization of structural characteristics of CD30 molecule
Generation of antagonistic biparatopic anti-CD30 antibody from an agonistic antibody by precise epitope determination and utilization of structural characteristics of CD30 molecule Open
Background CD30 is a member of the tumor necrosis factor receptor superfamily. Recently, blocking CD30-dependent intracellular signaling has emerged as potential strategy for immunological regulation. Development of antibody-based CD30 ant…
View article: Discovery of anti-SARS-CoV-2 S2 protein antibody CV804 with broad-spectrum reactivity with various beta coronaviruses and analysis of its pharmacological properties in vitro and in vivo
Discovery of anti-SARS-CoV-2 S2 protein antibody CV804 with broad-spectrum reactivity with various beta coronaviruses and analysis of its pharmacological properties in vitro and in vivo Open
The SARS-CoV-2 pandemic alerted the potential for significant harm due to future cross-species transmission of various animal coronaviruses to human. There is a significant need of antibody-based drugs to treat patients infected with previ…
View article: Generation of antagonistic biparatopic anti-CD30 antibody from an agonistic antibody by precise epitope determination and utilization of structural characteristics of CD30 molecule
Generation of antagonistic biparatopic anti-CD30 antibody from an agonistic antibody by precise epitope determination and utilization of structural characteristics of CD30 molecule Open
CD30 is a type I membrane protein that has been successfully targeted for lymphoma therapy using Brentuximab vedotin, an antibody-drug conjugate. Recently, the potential of blocking CD30-dependent NF-κB intracellular signaling has gained a…
View article: Crystal structures of human CD40 in complex with monoclonal antibodies dacetuzumab and bleselumab
Crystal structures of human CD40 in complex with monoclonal antibodies dacetuzumab and bleselumab Open
CD40 is a member of the tumor necrosis factor receptor superfamily, and it is widely expressed on immune and non-immune cell types. The interaction between CD40 and the CD40 ligand (CD40L) plays an essential function in signaling, and the …
View article: Discovery of anti-SARS-CoV-2 S2 protein antibody CV804 with broad-spectrum reactivity with various beta coronaviruses and analysis of its pharmacological properties in vitro and in vivo
Discovery of anti-SARS-CoV-2 S2 protein antibody CV804 with broad-spectrum reactivity with various beta coronaviruses and analysis of its pharmacological properties in vitro and in vivo Open
SARS-CoV-2 pandemic alerts us that spillovers of various animal coronaviruses to human in the future may bring us enormous damages. Thus, there is a significant need of antibody-based drugs to treat patients infected with previously unseen…
View article: Development of a 1:1-binding biparatopic anti-TNFR2 antagonist by reducing signaling activity through epitope selection
Development of a 1:1-binding biparatopic anti-TNFR2 antagonist by reducing signaling activity through epitope selection Open
View article: Development of a 1:1-binding biparatopic anti-TNFR2 antagonist by epitope selection
Development of a 1:1-binding biparatopic anti-TNFR2 antagonist by epitope selection Open
Conventional bivalent antibodies against cell surface receptors often initiate unwanted signal transduction by crosslinking two antigen molecules. Biparatopic antibodies (BpAbs) bind to two different epitopes on the same antigen, thus alte…
View article: Production of IgG1-based bispecific antibody without extra cysteine residue via intein-mediated protein trans-splicing
Production of IgG1-based bispecific antibody without extra cysteine residue via intein-mediated protein trans-splicing Open
A major class of bispecific antibodies (BsAbs) utilizes heterodimeric Fc to produce the native immunoglobulin G (IgG) structure. Because appropriate pairing of heavy and light chains is required, the design of BsAbs produced through recomb…
View article: Preclinical development of anti-BCMA immunotoxins targeting multiple myeloma
Preclinical development of anti-BCMA immunotoxins targeting multiple myeloma Open
Background Multiple myeloma (MM) is a B-cell malignancy that is incurable for the majority of patients. New treatments are urgently needed. Recombinant immunotoxins (RITs) are chimeric proteins that are composed of the Fv or Fab portion of…
View article: Clinical significance of MUC13 in pancreatic ductal adenocarcinoma
Clinical significance of MUC13 in pancreatic ductal adenocarcinoma Open
View article: Recombinant immunotoxins targeting B-cell maturation antigen are cytotoxic to myeloma cell lines and myeloma cells from patients
Recombinant immunotoxins targeting B-cell maturation antigen are cytotoxic to myeloma cell lines and myeloma cells from patients Open
View article: MUC13 interaction with receptor tyrosine kinase HER2 drives pancreatic ductal adenocarcinoma progression
MUC13 interaction with receptor tyrosine kinase HER2 drives pancreatic ductal adenocarcinoma progression Open